bearish

AptaBio Therapeutics

AptaBio Therapeutics (293780 KS): Near-Term Cash Crunch Is Clouding Promising Prospects of Pipeline

Despite announcing a positive topline result from phase 2 trial of its lead candidate APX-115, AptaBio’s growth potential will largely depend on its funding position and out licensing capacity.

Equity Bottom-Up
162 Views, 22 Sep 2022 22:32
SUMMARY(Sign Up to Access)
or
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
Logo
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Health CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
x